登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ●回购注销原因：经四川路桥建设集团股份有限公司（以下简称公司或四川路桥）第八届董事会第五十 七次会议审议，鉴于公司《2021年限制性股票激励计划（草案）》（以下简称《2021年激励计划》）首 次授予的6名激励对象在第二个解除限售期因故出现《2021年激励计划》规定的不能解除限售或者不能 全部解除限售的情形，公司将对前述6名激励对象第二个解除限售期不能解除限售的105,840股限制性股 票进行回购注销；同时，《2021年激励计划》首次及预留部分第三个解除限售期的解除限售条件中公司 层面业绩考核指标未达到规定的解除限售条件，公司将对第三个解除限售期对应的14,343,000股限制性 股票予以回购注销。综上，公司本次将回购注销14,448,840股已获授但尚未解除限售的限制性股票。 ●本次注销股份的有关情况 ■ 一、本次限制性股票回购注销的决策与信息披露 1、2025年6月27日，公司召开第八届董事会第五十七次会议、第八 ...

Core Viewpoint - The legal opinion letter from Guangdong Xinda Law Firm confirms that Kangmei Pharmaceutical Co., Ltd.'s plan to repurchase and cancel unvested restricted stocks under its first and second stock incentive plans complies with relevant laws and regulations [4][6][8]. Summary by Sections Repurchase and Cancellation Conditions - The decision to terminate the first and second stock incentive plans and repurchase unvested restricted stocks is based on the provisions of the Management Measures and has been approved by the company's board and shareholders [4][6]. Decision-Making Process and Information Disclosure - On September 14, 2021, the company held meetings to approve the termination of the first and second stock incentive plans and the repurchase of unvested stocks, with independent directors expressing agreement [6][7]. - The company disclosed the resolutions through official announcements [7]. Involved Parties, Share Quantity, and Cancellation Date - The repurchase involves 816 incentive recipients [8]. - The total number of shares to be repurchased and canceled is 34.97 million shares [8]. - The company has applied for the necessary procedures with the China Securities Depository and Clearing Corporation [8]. Conclusion - The legal opinion concludes that the repurchase and cancellation process meets all necessary legal and regulatory requirements [8].